More than 7,000 people in the United Kingdom placed orders for the newly launched Wegovy weight-loss pills within a day of their release at select pharmacies, including Asda, which reported over 13,000 enquiries in two weeks. Wegovy is the first GLP-1 receptor agonist pill approved by the UK’s medicines regulator for weight management, offering an alternative to existing injectable treatments. The medication, produced by Danish pharmaceutical company Novo Nordisk, is available in 1.5mg and 4mg doses, with prices ranging from approximately £99 to £119 per pack through online pharmacy services.
Wegovy contains semaglutide, the active ingredient also found in Novo Nordisk’s injectable GLP-1 drugs used for diabetes and obesity treatment. While some patients using the pill have prior experience with injectable GLP-1 therapies, the majority are new to such medications and prefer the oral administration over injections. Pharmacists at Asda have emphasized their readiness to support patients through consultations, encouraging lifestyle changes alongside the medication to improve outcomes. The retailer noted an associated rise in sales of health-oriented products, including low-alcohol drinks, high-protein foods, and fresh ingredients, indicating a broader shift toward healthier living among customers.
The pill is currently available only through private prescriptions and is not offered on the National Health Service (NHS). This has led to individuals seeking access through private channels, with some users sharing positive personal experiences from countries where the pill was approved earlier, such as the United States.
One US user, police officer Heather McCall from Virginia, reported significant benefits after starting the Wegovy pill in February. Having struggled with severe obesity and related health issues, she lost over 3 stone within five months of treatment, alongside notable improvements in energy levels, digestive health, and sleep quality. McCall described a marked reduction in food cravings and a shift toward a high-protein, low-carbohydrate diet. Similarly, another US user who supplemented weight loss post-gastric sleeve surgery credited the pill with helping reach her target weight after a plateau.
Medical professionals caution that while clinical trials suggest the pill delivers weight-loss results comparable to its injectable counterparts—with average weight reduction around 14 percent after 64 weeks—Wegovy is not a standalone "magic pill." It must be used under medical supervision and combined with lifestyle adjustments. Common side effects include gastrointestinal symptoms such as nausea, constipation, and diarrhea, especially during initial weeks. More severe but rare risks include pancreatitis, gallbladder issues, and dehydration-related complications.
Pharmacists note that the oral pill requires daily dosing and careful timing, typically taken in the morning before daily activities, contrasting with the once-weekly injection schedule. Some patients may prefer the convenience or the avoidance of injections, but clinical guidance remains essential to balance benefits and potential side effects.
As interest in the Wegovy pill grows, health experts stress the importance of comprehensive care, noting that weight management involves multiple facets beyond medication alone. The drug’s introduction marks a notable development in obesity treatment options within the UK, expanding choices for patients seeking medical assistance alongside lifestyle efforts.